Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer

Prostate Stereotactic ablative body radiotherapy (SABR) is an established technique that delivers radiation in a non-invasive approach for men with prostate cancer. The treatment regimen is given in total of 5 fractions with one treatment per day at every other day or weekly sessions. Ultra-hypofractionated radiotherapy (UHRT) is an emerging monotherapy for localized prostate cancer however, several trials have observed demonstrating superior biochemical control of a two-fraction (HDR) over single-fraction approach. The study aims to compare an experimental shorter course of prostate ultra-hyp

Trial Details

NCT ID

NCT05600400

Phase

NA

Sponsor

Sunnybrook Health Sciences Centre

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Stereotactic Ablative Body Radiation

Locations (sample)

• Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

• Histologically confirmed prostate adenocarcinoma (centrally reviewed)
• Low or favorable intermediate risk disease. Patient must meet one of the following categories:
• Low risk - T1-T2b, grade group 1, AND PSA \< 10 ng/ml;
• Favorable risk

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →